SPCC (Sharing Progress in Cancer Care) shared a post on LinkedIn:
“We are pleased to announce the fifth webinar in the Definitive Trial series, focusing on the latest advancements in the neo/adjuvant treatment of HER2-positive breast cancer.
This session will explore current standards of care and the key factors guiding treatment individualisation. Our panel of experts will discuss the implications for surgical decision-making within a multidisciplinary setting, drawing on the latest clinical evidence and real-world practice.
Discussant: Alexandru Eniu, CH
Experts: Roisin Connolly, IE, and Adrienne G. Waks, US
- Thursday, 23 April 2026; 18:00 CEST
- CME accredited
Funded by the European Union – Horizon Europe Grant Agreement No. 101136953. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HADEA.
Neither the European Union nor the granting authority can be held responsible for them. This work has also received funding from the Swiss State Secretariat for Education, Research and Innovation (SERI).”
Other articles featuring SPCC on OncoDaily.